DNA Relative Valuation
DNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNA is overvalued; if below, it's undervalued.
Historical Valuation
Ginkgo Bioworks Holdings Inc (DNA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.28. The fair price of Ginkgo Bioworks Holdings Inc (DNA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：9.21
Fair
-1.98
PE
1Y
3Y
5Y
Trailing
Forward
-3.76
EV/EBITDA
Ginkgo Bioworks Holdings Inc. (DNA) has a current EV/EBITDA of -3.76. The 5-year average EV/EBITDA is -17.99. The thresholds are as follows: Strongly Undervalued below -87.31, Undervalued between -87.31 and -52.65, Fairly Valued between 16.67 and -52.65, Overvalued between 16.67 and 51.33, and Strongly Overvalued above 51.33. The current Forward EV/EBITDA of -3.76 falls within the Historic Trend Line -Fairly Valued range.
-1.74
EV/EBIT
Ginkgo Bioworks Holdings Inc. (DNA) has a current EV/EBIT of -1.74. The 5-year average EV/EBIT is -9.50. The thresholds are as follows: Strongly Undervalued below -64.20, Undervalued between -64.20 and -36.85, Fairly Valued between 17.86 and -36.85, Overvalued between 17.86 and 45.21, and Strongly Overvalued above 45.21. The current Forward EV/EBIT of -1.74 falls within the Historic Trend Line -Fairly Valued range.
2.88
PS
Ginkgo Bioworks Holdings Inc. (DNA) has a current PS of 2.88. The 5-year average PS is 12.82. The thresholds are as follows: Strongly Undervalued below -16.30, Undervalued between -16.30 and -1.74, Fairly Valued between 27.38 and -1.74, Overvalued between 27.38 and 41.94, and Strongly Overvalued above 41.94. The current Forward PS of 2.88 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Ginkgo Bioworks Holdings Inc. (DNA) has a current P/OCF of 0.00. The 5-year average P/OCF is -16.11. The thresholds are as follows: Strongly Undervalued below -72.48, Undervalued between -72.48 and -44.29, Fairly Valued between 12.08 and -44.29, Overvalued between 12.08 and 40.27, and Strongly Overvalued above 40.27. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Ginkgo Bioworks Holdings Inc. (DNA) has a current P/FCF of 0.00. The 5-year average P/FCF is -13.45. The thresholds are as follows: Strongly Undervalued below -58.80, Undervalued between -58.80 and -36.13, Fairly Valued between 9.22 and -36.13, Overvalued between 9.22 and 31.90, and Strongly Overvalued above 31.90. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Ginkgo Bioworks Holdings Inc (DNA) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 1.49 , the current P/B ratio is approximately -37.42% higher. Relative to its 5-year average P/B ratio of 3.21, the current P/B ratio is about -70.91% higher. Ginkgo Bioworks Holdings Inc (DNA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -37.72%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -26.61% , the current FCF yield is about -100.00% lower.
0.94
P/B
Median3y
1.49
Median5y
3.21
-36.55
FCF Yield
Median3y
-37.72
Median5y
-26.61
Competitors Valuation Multiple
The average P/S ratio for DNA's competitors is , providing a benchmark for relative valuation. Ginkgo Bioworks Holdings Inc Corp (DNA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -56.39%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DNA decreased by 6.21% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -63.34 to -207.93.
The secondary factor is the Revenue Growth, contributed -56.39%to the performance.
Overall, the performance of DNA in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Ginkgo Bioworks Holdings Inc (DNA) currently overvalued or undervalued?
What is Ginkgo Bioworks Holdings Inc (DNA) fair value?
How does DNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Dec 05 2025?
What is the current FCF Yield for Ginkgo Bioworks Holdings Inc (DNA) as of Dec 05 2025?
What is the current Forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Dec 05 2025?